Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
Page 1 of 1
Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
Jon Moulton Wed Aug 17, 2016 4:01 pm
Hildyard JC, Wells DJ. Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy. PLoS Curr. 2016 Jun 16;8. pii: ecurrents.md.99d88e72634387639707601b237467d7. doi: 10.1371/currents.md.99d88e72634387639707601b237467d7.
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 62
Location : Philomath, Oregon, USA -
Similar topics» CPP-Directed Oligonucleotide Exon Skipping in Animal Models of Duchenne Muscular Dystrophy
» Targeting mRNA Splicing as a Potential Treatment for Duchenne Muscular Dystrophy
» Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
» Eteplirsen for the treatment of duchenne muscular dystrophy
» Exon-skipping therapy for Duchenne muscular dystrophy
» Targeting mRNA Splicing as a Potential Treatment for Duchenne Muscular Dystrophy
» Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
» Eteplirsen for the treatment of duchenne muscular dystrophy
» Exon-skipping therapy for Duchenne muscular dystrophy
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum